Archives
-
O-propargyl-puromycin (OPP) for Protein Synthesis
2026-08-19
O-propargyl-puromycin (OPP) converts a short metabolic pulse into a quantitative readout of nascent protein production, making it useful for flow cytometry, imaging, and enrichment workflows. Applied to the Pcbp1–mitochondrial phenotype in B cells, it can distinguish altered translation from changes in steady-state antibody abundance while preserving single-cell resolution.
-
Phosphatase Inhibitor Cocktail for Phosphoproteomics
2026-08-19
Protect phosphorylation-dependent signals from lysis through immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry with a dual-component 100X inhibitor system. Its sequential Tube A/Tube B format supports broad serine/threonine and tyrosine phosphatase control while enabling more faithful analysis of signaling mechanisms such as the OTUD3–cGAS pathway.
-
3-(1-methylpyrrolidin-2-yl)pyridine in Arrhythmia Assays
2026-08-18
Use N2703 as a controlled perturbation variable in adipose–neural–cardiomyocyte co-culture experiments, not as a presumed pathway-specific inhibitor. Its documented solubility and high purity support dose-ranging, compartment-specific testing, and orthogonal validation of signaling changes linked to arrhythmogenesis.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-18
This study identifies striatal D2 receptor-expressing medium spiny neurons as a cell-type-specific circuit node linking Neuroligin 1 loss to autistic-like repetitive behaviors. Its combination of behavioral analysis, activity manipulation, single-nucleus RNA sequencing, and protein validation implicates excessive PKC signaling in D2-MSN hyperexcitability and distinguishes the activity patterns associated with self-grooming and digging.
-
Phosphatase Inhibitor Cocktail 1 for Metabolic Signaling
2026-08-17
Phosphatase Inhibitor Cocktail 1 helps preserve phosphorylation-dependent information during tissue and cell sample preparation. This article connects inhibitor selection with metabolic heterogeneity in posterior fossa malignancies and provides a practical framework for phosphoproteomic analysis, Western blotting, and kinase assays.
-
Trelagliptin, RUNX2, and Osteoblast Differentiation
2026-08-17
The reference study shows that the DPP-4 inhibitor trelagliptin promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells, with increased RUNX2 and AMPK phosphorylation. Its findings provide a mechanistic preclinical rationale for investigating trelagliptin in bone biology, while remaining insufficient to establish clinical efficacy in osteoporosis.
-
SmCPK20–SmWRKY2 Control of Tanshinone Synthesis
2026-08-16
The reference study identifies a calcium-dependent protein kinase, SmCPK20, as an upstream regulator that phosphorylates the transcription factor SmWRKY2 at Thr-256 during jasmonate signaling in Salvia miltiorrhiza. This modification strengthens SmWRKY2 activation of SmCPS1 and provides a mechanistic link between jasmonate perception, calcium signaling, and tanshinone biosynthesis.
-
Recombinant Human Growth Hormone: GH Assay Workflows
2026-08-15
Build reproducible chondrocyte proliferation, differentiation, and IGF-1 pathway experiments with a defined recombinant GH workflow. The approach combines dose–time optimization with IGFBP2 loss- and gain-of-function controls to distinguish simple growth effects from mechanism-specific signaling.
-
CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer
2026-08-14
This study identifies a paracrine ANGPTL4–IQGAP1 signaling axis through which cancer-associated fibroblasts remodel mitochondrial metabolism and reduce chemotherapy sensitivity in prostate cancer. Its findings connect the tumor microenvironment with Raf–MEK–ERK–PGC1α signaling, OXPHOS, and a potential pharmacological strategy involving QGGP and docetaxel.
-
Fenipentol Workflow for GI Secretion Studies
2026-08-14
Fenipentol, also called 1-Phenyl-1-pentanol, supports controlled investigations of pancreatobiliary secretion, lipase activity, and ESR1-linked signaling. This practical guide separates product-specific evidence from exploratory assay recommendations and highlights a critical nomenclature distinction in hepatic fibrosis research.
-
Tricine-SDS-PAGE Electrophoresis System Guide
2026-08-13
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is intended for resolving low-molecular-weight proteins and peptides that may be poorly separated by conventional Tris-glycine SDS-PAGE. It supports research workflows involving denaturing or non-denaturing electrophoresis, but it is not intended for diagnostic, clinical, or medical use.
-
Novobiocin Hybrids Show Anti-Toxoplasma Activity
2026-08-13
A 2024 Acta Parasitologica study tested quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. Several candidates, together with novobiocin, reduced parasite infection, proliferation, and plaque formation while showing greater selectivity than pyrimethamine in the reported cell-based assays.
-
CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer
2026-08-12
This study identifies a paracrine ANGPTL4–IQGAP1 signaling axis through which cancer-associated fibroblasts enhance mitochondrial biogenesis, oxidative phosphorylation, and chemotherapy resistance in prostate cancer. Its integrated proteomic, metabolomic, interaction, and pharmacological analyses suggest that targeting tumor–stroma metabolic communication may improve docetaxel responsiveness, while also defining important requirements for mechanistic validation.
-
BMS 309403: A Causal Assay Framework for FABP4
2026-08-12
BMS 309403 is a selective FABP4 inhibitor for dissecting lipid-driven inflammation, foam-cell formation, and cardiometabolic signaling. This article presents a causal, assay-oriented framework that connects target engagement with the SERCA2/CaN/FoxO1/FABP4 pathway and distinguishes pharmacological evidence from genetic validation.
-
FPR2/ALX, Microglia, and NK Cells in Astrocytopathy
2026-08-11
Qi and colleagues show that activating FPR2/ALX with Quin-C1 restricts autoimmune astrocytopathy in mice by reshaping microglial and natural killer cell responses. The study connects these cellular effects with SYK-AKT signaling and provides a mechanistic framework for investigating neuroinflammation in AQP4-IgG-associated disease.